Loading…

The psychological impact of disclosing amyloid status to Japanese elderly: a preliminary study on asymptomatic patients with subjective cognitive decline

In Japan, 4.6 million people are living with dementia and the number is expected to rise to 7 million by 2025. Amyloid-β (Aβ) positron emission tomography (PET) is used for cognitively normal Japanese people with or without subjective cognitive decline (SCD) for the purpose of clinical trials or dia...

Full description

Saved in:
Bibliographic Details
Published in:International psychogeriatrics 2018-05, Vol.30 (5), p.635-639
Main Authors: Wake, Taisei, Tabuchi, Hajime, Funaki, Kei, Ito, Daisuke, Yamagata, Bun, Yoshizaki, Takahito, Kameyama, Masashi, Nakahara, Tadaki, Murakami, Koji, Jinzaki, Masahiro, Mimura, Masaru
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c373t-6d47c7a6a2c024c05c06411e01effba063d3b3dfe1ac7dc8b86cd4b4585fdd0a3
cites cdi_FETCH-LOGICAL-c373t-6d47c7a6a2c024c05c06411e01effba063d3b3dfe1ac7dc8b86cd4b4585fdd0a3
container_end_page 639
container_issue 5
container_start_page 635
container_title International psychogeriatrics
container_volume 30
creator Wake, Taisei
Tabuchi, Hajime
Funaki, Kei
Ito, Daisuke
Yamagata, Bun
Yoshizaki, Takahito
Kameyama, Masashi
Nakahara, Tadaki
Murakami, Koji
Jinzaki, Masahiro
Mimura, Masaru
description In Japan, 4.6 million people are living with dementia and the number is expected to rise to 7 million by 2025. Amyloid-β (Aβ) positron emission tomography (PET) is used for cognitively normal Japanese people with or without subjective cognitive decline (SCD) for the purpose of clinical trials or diagnosis. Nevertheless, no empirical studies have been conducted on the safety of disclosing amyloid status to such populations. We conducted amyloid PET imaging on 42 participants (Aβ positive (n = 10) and negative (n = 32)). State anxiety and depression were measured at pre- and post-disclosure, and test-related distress at post-disclosure. Mean state anxiety and depression scores were below the cut-off through pre- and post-disclosure in the Aβ positive and negative groups. State anxiety and depression did not change over time and were not different between groups. Mean test-related distress scores were within normal limits at post-disclosure in both groups. No significant difference was found between groups. Disclosing Aβ positive results did not cause greater mood disturbance than negative results in a short period of time. The short-term psychological safety of disclosing Aβ PET results to asymptomatic Japanese adults with SCD was indicated.
doi_str_mv 10.1017/S1041610217002204
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1959323652</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><cupid>10_1017_S1041610217002204</cupid><sourcerecordid>1959323652</sourcerecordid><originalsourceid>FETCH-LOGICAL-c373t-6d47c7a6a2c024c05c06411e01effba063d3b3dfe1ac7dc8b86cd4b4585fdd0a3</originalsourceid><addsrcrecordid>eNp1kctu1TAQhi1ERW88ABtkiQ2bUN_inLBDVaGgSl20lbqLHHtyjo_sONhOqzwKb4vbHqhUxGZmpPnmt2d-hN5R8okS2pxcUSKopITRhhDGiHiFDmgjaMUIv31d6tKuHvr76DClbWFqTsUbtM9a0gpZywP063oDeEqL3gQX1lYrh62flM44DNjYpF1Idlxj5RcXrMEpqzwnnAP-oSY1QgIMzkB0y2es8BTBWW9HFZdCzmbBYcQqLX7KwatsNZ5KhDEnfG_zBqe534LO9g6wDuvRPlYGtLMjHKO9QbkEb3f5CN18Pbs-Pa8uLr99P_1yUWne8FxJIxrdKKmYJkxoUmsiBaVAKAxDr4jkhvfcDECVboxe9SupjehFvaoHY4jiR-jjk-4Uw88ZUu58WRucK9uFOXW0rVvOuKxZQT-8QLdhjmP5XVeO3wguWyEKRZ8oHUNKEYZuitaXk3SUdA--df_4Vmbe75Tn3oP5O_HHqALwnajyfbRmDc9v_1_2N76kpgg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2047436944</pqid></control><display><type>article</type><title>The psychological impact of disclosing amyloid status to Japanese elderly: a preliminary study on asymptomatic patients with subjective cognitive decline</title><source>Applied Social Sciences Index &amp; Abstracts (ASSIA)</source><source>Social Science Premium Collection</source><source>Sociology Collection</source><source>Cambridge University Press</source><creator>Wake, Taisei ; Tabuchi, Hajime ; Funaki, Kei ; Ito, Daisuke ; Yamagata, Bun ; Yoshizaki, Takahito ; Kameyama, Masashi ; Nakahara, Tadaki ; Murakami, Koji ; Jinzaki, Masahiro ; Mimura, Masaru</creator><creatorcontrib>Wake, Taisei ; Tabuchi, Hajime ; Funaki, Kei ; Ito, Daisuke ; Yamagata, Bun ; Yoshizaki, Takahito ; Kameyama, Masashi ; Nakahara, Tadaki ; Murakami, Koji ; Jinzaki, Masahiro ; Mimura, Masaru</creatorcontrib><description>In Japan, 4.6 million people are living with dementia and the number is expected to rise to 7 million by 2025. Amyloid-β (Aβ) positron emission tomography (PET) is used for cognitively normal Japanese people with or without subjective cognitive decline (SCD) for the purpose of clinical trials or diagnosis. Nevertheless, no empirical studies have been conducted on the safety of disclosing amyloid status to such populations. We conducted amyloid PET imaging on 42 participants (Aβ positive (n = 10) and negative (n = 32)). State anxiety and depression were measured at pre- and post-disclosure, and test-related distress at post-disclosure. Mean state anxiety and depression scores were below the cut-off through pre- and post-disclosure in the Aβ positive and negative groups. State anxiety and depression did not change over time and were not different between groups. Mean test-related distress scores were within normal limits at post-disclosure in both groups. No significant difference was found between groups. Disclosing Aβ positive results did not cause greater mood disturbance than negative results in a short period of time. The short-term psychological safety of disclosing Aβ PET results to asymptomatic Japanese adults with SCD was indicated.</description><identifier>ISSN: 1041-6102</identifier><identifier>EISSN: 1741-203X</identifier><identifier>DOI: 10.1017/S1041610217002204</identifier><identifier>PMID: 29094656</identifier><language>eng</language><publisher>Cambridge, UK: Cambridge University Press</publisher><subject>Aged ; Aged, 80 and over ; Alzheimer Disease - diagnostic imaging ; Alzheimer Disease - psychology ; Alzheimer's disease ; Amyloid beta-Peptides - analysis ; Anxiety ; Anxiety - etiology ; Brain - diagnostic imaging ; Dementia ; Depression - etiology ; Disclosure - ethics ; Education ; Female ; Geriatrics ; Humans ; Japan ; Male ; Medical ethics ; Medical imaging ; Memory ; Neurology ; Neuropsychological Tests ; NMR ; Nuclear magnetic resonance ; Nuclear medicine ; Older people ; Personal health ; Positron-Emission Tomography - adverse effects ; Positron-Emission Tomography - ethics ; Psychiatrists ; Psychological safety ; Variance analysis</subject><ispartof>International psychogeriatrics, 2018-05, Vol.30 (5), p.635-639</ispartof><rights>Copyright © International Psychogeriatric Association 2017</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c373t-6d47c7a6a2c024c05c06411e01effba063d3b3dfe1ac7dc8b86cd4b4585fdd0a3</citedby><cites>FETCH-LOGICAL-c373t-6d47c7a6a2c024c05c06411e01effba063d3b3dfe1ac7dc8b86cd4b4585fdd0a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2047436944/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$H</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2047436944?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,780,784,12846,21394,21395,27924,27925,30999,33611,33612,34530,34531,43733,44115,72960,74221,74639</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29094656$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wake, Taisei</creatorcontrib><creatorcontrib>Tabuchi, Hajime</creatorcontrib><creatorcontrib>Funaki, Kei</creatorcontrib><creatorcontrib>Ito, Daisuke</creatorcontrib><creatorcontrib>Yamagata, Bun</creatorcontrib><creatorcontrib>Yoshizaki, Takahito</creatorcontrib><creatorcontrib>Kameyama, Masashi</creatorcontrib><creatorcontrib>Nakahara, Tadaki</creatorcontrib><creatorcontrib>Murakami, Koji</creatorcontrib><creatorcontrib>Jinzaki, Masahiro</creatorcontrib><creatorcontrib>Mimura, Masaru</creatorcontrib><title>The psychological impact of disclosing amyloid status to Japanese elderly: a preliminary study on asymptomatic patients with subjective cognitive decline</title><title>International psychogeriatrics</title><addtitle>Int. Psychogeriatr</addtitle><description>In Japan, 4.6 million people are living with dementia and the number is expected to rise to 7 million by 2025. Amyloid-β (Aβ) positron emission tomography (PET) is used for cognitively normal Japanese people with or without subjective cognitive decline (SCD) for the purpose of clinical trials or diagnosis. Nevertheless, no empirical studies have been conducted on the safety of disclosing amyloid status to such populations. We conducted amyloid PET imaging on 42 participants (Aβ positive (n = 10) and negative (n = 32)). State anxiety and depression were measured at pre- and post-disclosure, and test-related distress at post-disclosure. Mean state anxiety and depression scores were below the cut-off through pre- and post-disclosure in the Aβ positive and negative groups. State anxiety and depression did not change over time and were not different between groups. Mean test-related distress scores were within normal limits at post-disclosure in both groups. No significant difference was found between groups. Disclosing Aβ positive results did not cause greater mood disturbance than negative results in a short period of time. The short-term psychological safety of disclosing Aβ PET results to asymptomatic Japanese adults with SCD was indicated.</description><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Alzheimer Disease - diagnostic imaging</subject><subject>Alzheimer Disease - psychology</subject><subject>Alzheimer's disease</subject><subject>Amyloid beta-Peptides - analysis</subject><subject>Anxiety</subject><subject>Anxiety - etiology</subject><subject>Brain - diagnostic imaging</subject><subject>Dementia</subject><subject>Depression - etiology</subject><subject>Disclosure - ethics</subject><subject>Education</subject><subject>Female</subject><subject>Geriatrics</subject><subject>Humans</subject><subject>Japan</subject><subject>Male</subject><subject>Medical ethics</subject><subject>Medical imaging</subject><subject>Memory</subject><subject>Neurology</subject><subject>Neuropsychological Tests</subject><subject>NMR</subject><subject>Nuclear magnetic resonance</subject><subject>Nuclear medicine</subject><subject>Older people</subject><subject>Personal health</subject><subject>Positron-Emission Tomography - adverse effects</subject><subject>Positron-Emission Tomography - ethics</subject><subject>Psychiatrists</subject><subject>Psychological safety</subject><subject>Variance analysis</subject><issn>1041-6102</issn><issn>1741-203X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>7QJ</sourceid><sourceid>ALSLI</sourceid><sourceid>HEHIP</sourceid><sourceid>M2R</sourceid><sourceid>M2S</sourceid><recordid>eNp1kctu1TAQhi1ERW88ABtkiQ2bUN_inLBDVaGgSl20lbqLHHtyjo_sONhOqzwKb4vbHqhUxGZmpPnmt2d-hN5R8okS2pxcUSKopITRhhDGiHiFDmgjaMUIv31d6tKuHvr76DClbWFqTsUbtM9a0gpZywP063oDeEqL3gQX1lYrh62flM44DNjYpF1Idlxj5RcXrMEpqzwnnAP-oSY1QgIMzkB0y2es8BTBWW9HFZdCzmbBYcQqLX7KwatsNZ5KhDEnfG_zBqe534LO9g6wDuvRPlYGtLMjHKO9QbkEb3f5CN18Pbs-Pa8uLr99P_1yUWne8FxJIxrdKKmYJkxoUmsiBaVAKAxDr4jkhvfcDECVboxe9SupjehFvaoHY4jiR-jjk-4Uw88ZUu58WRucK9uFOXW0rVvOuKxZQT-8QLdhjmP5XVeO3wguWyEKRZ8oHUNKEYZuitaXk3SUdA--df_4Vmbe75Tn3oP5O_HHqALwnajyfbRmDc9v_1_2N76kpgg</recordid><startdate>201805</startdate><enddate>201805</enddate><creator>Wake, Taisei</creator><creator>Tabuchi, Hajime</creator><creator>Funaki, Kei</creator><creator>Ito, Daisuke</creator><creator>Yamagata, Bun</creator><creator>Yoshizaki, Takahito</creator><creator>Kameyama, Masashi</creator><creator>Nakahara, Tadaki</creator><creator>Murakami, Koji</creator><creator>Jinzaki, Masahiro</creator><creator>Mimura, Masaru</creator><general>Cambridge University Press</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0-V</scope><scope>3V.</scope><scope>7QJ</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88G</scope><scope>88J</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ALSLI</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HEHIP</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>M2M</scope><scope>M2O</scope><scope>M2R</scope><scope>M2S</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>201805</creationdate><title>The psychological impact of disclosing amyloid status to Japanese elderly: a preliminary study on asymptomatic patients with subjective cognitive decline</title><author>Wake, Taisei ; Tabuchi, Hajime ; Funaki, Kei ; Ito, Daisuke ; Yamagata, Bun ; Yoshizaki, Takahito ; Kameyama, Masashi ; Nakahara, Tadaki ; Murakami, Koji ; Jinzaki, Masahiro ; Mimura, Masaru</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c373t-6d47c7a6a2c024c05c06411e01effba063d3b3dfe1ac7dc8b86cd4b4585fdd0a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Alzheimer Disease - diagnostic imaging</topic><topic>Alzheimer Disease - psychology</topic><topic>Alzheimer's disease</topic><topic>Amyloid beta-Peptides - analysis</topic><topic>Anxiety</topic><topic>Anxiety - etiology</topic><topic>Brain - diagnostic imaging</topic><topic>Dementia</topic><topic>Depression - etiology</topic><topic>Disclosure - ethics</topic><topic>Education</topic><topic>Female</topic><topic>Geriatrics</topic><topic>Humans</topic><topic>Japan</topic><topic>Male</topic><topic>Medical ethics</topic><topic>Medical imaging</topic><topic>Memory</topic><topic>Neurology</topic><topic>Neuropsychological Tests</topic><topic>NMR</topic><topic>Nuclear magnetic resonance</topic><topic>Nuclear medicine</topic><topic>Older people</topic><topic>Personal health</topic><topic>Positron-Emission Tomography - adverse effects</topic><topic>Positron-Emission Tomography - ethics</topic><topic>Psychiatrists</topic><topic>Psychological safety</topic><topic>Variance analysis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wake, Taisei</creatorcontrib><creatorcontrib>Tabuchi, Hajime</creatorcontrib><creatorcontrib>Funaki, Kei</creatorcontrib><creatorcontrib>Ito, Daisuke</creatorcontrib><creatorcontrib>Yamagata, Bun</creatorcontrib><creatorcontrib>Yoshizaki, Takahito</creatorcontrib><creatorcontrib>Kameyama, Masashi</creatorcontrib><creatorcontrib>Nakahara, Tadaki</creatorcontrib><creatorcontrib>Murakami, Koji</creatorcontrib><creatorcontrib>Jinzaki, Masahiro</creatorcontrib><creatorcontrib>Mimura, Masaru</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Social Sciences Premium Collection【Remote access available】</collection><collection>ProQuest Central (Corporate)</collection><collection>Applied Social Sciences Index &amp; Abstracts (ASSIA)</collection><collection>Nursing &amp; Allied Health Database</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>Social Science Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>Social Science Premium Collection</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>Sociology Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Psychology Database (ProQuest)</collection><collection>Research Library</collection><collection>ProQuest Social Science Journals</collection><collection>Sociology Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>International psychogeriatrics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wake, Taisei</au><au>Tabuchi, Hajime</au><au>Funaki, Kei</au><au>Ito, Daisuke</au><au>Yamagata, Bun</au><au>Yoshizaki, Takahito</au><au>Kameyama, Masashi</au><au>Nakahara, Tadaki</au><au>Murakami, Koji</au><au>Jinzaki, Masahiro</au><au>Mimura, Masaru</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The psychological impact of disclosing amyloid status to Japanese elderly: a preliminary study on asymptomatic patients with subjective cognitive decline</atitle><jtitle>International psychogeriatrics</jtitle><addtitle>Int. Psychogeriatr</addtitle><date>2018-05</date><risdate>2018</risdate><volume>30</volume><issue>5</issue><spage>635</spage><epage>639</epage><pages>635-639</pages><issn>1041-6102</issn><eissn>1741-203X</eissn><abstract>In Japan, 4.6 million people are living with dementia and the number is expected to rise to 7 million by 2025. Amyloid-β (Aβ) positron emission tomography (PET) is used for cognitively normal Japanese people with or without subjective cognitive decline (SCD) for the purpose of clinical trials or diagnosis. Nevertheless, no empirical studies have been conducted on the safety of disclosing amyloid status to such populations. We conducted amyloid PET imaging on 42 participants (Aβ positive (n = 10) and negative (n = 32)). State anxiety and depression were measured at pre- and post-disclosure, and test-related distress at post-disclosure. Mean state anxiety and depression scores were below the cut-off through pre- and post-disclosure in the Aβ positive and negative groups. State anxiety and depression did not change over time and were not different between groups. Mean test-related distress scores were within normal limits at post-disclosure in both groups. No significant difference was found between groups. Disclosing Aβ positive results did not cause greater mood disturbance than negative results in a short period of time. The short-term psychological safety of disclosing Aβ PET results to asymptomatic Japanese adults with SCD was indicated.</abstract><cop>Cambridge, UK</cop><pub>Cambridge University Press</pub><pmid>29094656</pmid><doi>10.1017/S1041610217002204</doi><tpages>5</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1041-6102
ispartof International psychogeriatrics, 2018-05, Vol.30 (5), p.635-639
issn 1041-6102
1741-203X
language eng
recordid cdi_proquest_miscellaneous_1959323652
source Applied Social Sciences Index & Abstracts (ASSIA); Social Science Premium Collection; Sociology Collection; Cambridge University Press
subjects Aged
Aged, 80 and over
Alzheimer Disease - diagnostic imaging
Alzheimer Disease - psychology
Alzheimer's disease
Amyloid beta-Peptides - analysis
Anxiety
Anxiety - etiology
Brain - diagnostic imaging
Dementia
Depression - etiology
Disclosure - ethics
Education
Female
Geriatrics
Humans
Japan
Male
Medical ethics
Medical imaging
Memory
Neurology
Neuropsychological Tests
NMR
Nuclear magnetic resonance
Nuclear medicine
Older people
Personal health
Positron-Emission Tomography - adverse effects
Positron-Emission Tomography - ethics
Psychiatrists
Psychological safety
Variance analysis
title The psychological impact of disclosing amyloid status to Japanese elderly: a preliminary study on asymptomatic patients with subjective cognitive decline
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T22%3A21%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20psychological%20impact%20of%20disclosing%20amyloid%20status%20to%20Japanese%20elderly:%20a%20preliminary%20study%20on%20asymptomatic%20patients%20with%20subjective%20cognitive%20decline&rft.jtitle=International%20psychogeriatrics&rft.au=Wake,%20Taisei&rft.date=2018-05&rft.volume=30&rft.issue=5&rft.spage=635&rft.epage=639&rft.pages=635-639&rft.issn=1041-6102&rft.eissn=1741-203X&rft_id=info:doi/10.1017/S1041610217002204&rft_dat=%3Cproquest_cross%3E1959323652%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c373t-6d47c7a6a2c024c05c06411e01effba063d3b3dfe1ac7dc8b86cd4b4585fdd0a3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2047436944&rft_id=info:pmid/29094656&rft_cupid=10_1017_S1041610217002204&rfr_iscdi=true